



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION




Lipid C3

Item No. 39516

CAS Registry No.: 2639634-93-6
Formal Name: 1,1'-[[3-[4-[2-[[3-[bis(2-hydroxyhexadecyl)amino]-2-ethoxypropyl)](2-hydroxyhexadecyl)amino]ethyl]-1-piperazinyl]-2-ethoxypropyl]imino]bis-2-hexadecanol

Synonym: C16-6
MF: C₉₆H₁₉₇N₅O₇
FW: 1,533.6
Purity: ≥95%
Supplied as: A solution in ethanol
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Lipid C3 is supplied as a solution in ethanol. To change the solvent, simply evaporate the ethanol under a gentle stream of nitrogen and immediately add the solvent of choice. Lipid C3 is soluble in methanol and chloroform.

Description

Lipid C3 is an ionizable cationic lipid (pKa = 5.05-5.671).^{1,2} It has been used in the formation of lipid nanoparticles (LNPs) for the delivery of mRNA *in vitro* and *in vivo*.¹ Intracerebroventricular administration of LNPs containing lipid C3 and encapsulating mRNA encoding α -L-iduronidase (*Idua*) to neonates increase midbrain and hippocampal α -L-iduronidase enzyme activity and decrease forebrain, midbrain, and hippocampal glycosaminoglycan levels in an *Idua*-W392X mouse model of the lysosomal storage disorder mucopolysaccharidosis type I, also known as Hurler syndrome. Intracerebroventricular administration of LNPs containing lipid C3 and encapsulating an mRNA reporter to fetal macaques *in utero* increase brain GFP expression.

References

1. Palanki, R., Bose, S.K., Dave, A., *et al.* Ionizable lipid nanoparticles for therapeutic base editing of congenital brain disease. *ACS Nano* **17**(14), 13594-13610 (2023).
2. Billingsley, M.M., Singh, N., Ravikumar, P., *et al.* Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering. *Nano Lett.* **20**(3), 1578-1589 (2020).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/19/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM